Top Tweets for #Checkmate227
Post hoc results from #CheckMate227 part 1 showed that intracranial efficacy outcomes favored nivolumab plus ipilimumab versus chemotherapy in those with or without brain metastases.
Study in @JTOonline by @MartinReck2, @JulieBrahmer and colleagues ➡️ https://t.co/C6PGR6sdlP
#ASCO22 | Francesco Grossi about the amazing results of #CheckMate227 and #CheckMate9LA trials:
"From both studies we have confirmation of long survival with NIVO + IPI alone or in combination with chemotherapy." #NSCLC
🚨🔊💥@OncoAlert informative update of #Checkmate227 with 4y OS. Nivo+ipi continues to provide consist OS benefit in both ITT ( PD-L1+) but also in PD-L1 NEG group. Since no #EMA approval,IMO CM-9A covers this gap with short chemo to abolish deaths in 1st 6m @myESMO #lcsm #some
Four year follow up on CheckMate 227 now @JTOonline. OS favors 1L nivolumab + ipilimumab vs chemo for PDL1+ NSCLC (HR 0.76, 4y OS rate 29% vs 18%) and PDL1- (HR 0.64, 4y rate 24% vs 10%). Those who stop nivo/ipi for toxicity retain long term OS benefit.
https://t.co/jOsSPlDxDi
ヤーボイについての動画
⇒ https://t.co/HpAn0ua1L2 #アメブロ @ameba_officialより
新たな作用機序の免疫チェックポイント阻害薬であるヤーボイについてYouTube動画を作成しました。
#ヤーボイ
#イピリムマブ
#CheckMate227
#ASCO20 | Come armonizzare il trattamento in prima linea tra combinazione #nivolumab+#ipilimumab e chemioterapia nel #NSCLC? A questa domanda contribuiscono senza dubbio a rispondere i due trial #CheckMate227 Part 1 e #CheckMate9LA presentati all'@ASCO.
https://t.co/AbT8Z6Shs4
Don't miss our webinar today at 1:30pm with Winship's @RamalingamMD and @SagarLonialMD discussing #CheckMate227 and #DREAMM2 respectively, and providing an overview of Winship research featured at #ASCO20. Register for free at https://t.co/xs599kPG2a.
Our Vice Chair, @tnewsomdavis has written two blogs on studies presented at #ESMO19. Take a look at his summaries of the #FLAURA and #Checkmate227 studies. https://t.co/K51S9m5CBa
【非小細胞肺癌のNivo+IPI OS改善】
#m3
#CheckMate227
未治療ステージIV NSCLCを対象に、ニボルマブとイピリムマブ併用の効果をみた第III相試験
→PD-L1 1％以上でのOS中央値は
併用療法群17.1カ月
化学療法群14.9カ月（P＝0.007）
https://t.co/G1cImR3pqd
Ipi+ nivo improved OS in aNSCLC, regardless of PD-L1 (#Checkmate227), but the bar is still <2 years: what is more insightful?
Checkmate 227 Ipi+Nivo: OS improved, regardless of PD-L1, but is still <2 years @peters_solange #ESMO19 #lcsm #checkmate227
@marinagarassino @giorgioscaglio3 @StephenRameyMD @CarloGenova5 @g_mountzios @RobertoFerrara_ @RamalingamMD
小野&ブリストル社からのプレスリリース。checkmate-227試験のパート1aでニボルマブ＋低用量イピリムマブの有効性が示される。非小細胞肺癌でもIO-IO併用の時代が到来し��うですね😄
#ニボルマブ
#イピリムマブ
#checkmate227 https://t.co/rTHO3vdVrF
Interesting to know if in the big trials #Checkmate227 #Mystic we can see from subgroup analyses the clinical effect in patients who received radiotherapy. If this is true there can be a new era for #antiCTLA4 in #NSCLC #LCAM
great article, very interesting data: a must-read on RT/IO combination for NSCLC by our colleagues from @WeillCornel https://t.co/pBOROfQqMx @_ShankarSiva @marinagarassino @DrewMoghanaki @CVanpouilleBox @rweichselbaum @ACKoongMDPhD @gerryhanna @fifimcdrmh @NP_Rudqvist
Tumor mutational burden is an important and independent biomarker in advanced NSCLC per #CheckMate227 https://t.co/Uzr2twTHez
in another @NEJM publication & @AACR presentation, ipilimumab + nivo ⬆️ PFS vs chemo in 1st line metastatic NSCLC with high tumour mutational burden (TMB) (>10 mutations per megabase) assessed by CDx assay https://t.co/7NnW1uPmrp #lcsm #immunotherapy #checkmate227
News: Better #PFS with #nivolumab + #ipilimumab than with #chemotherapy in patients with advanced #NSCLC who have a high tumor mutational burden, Matthew Hellman (from @sloan_kettering) et al report at #AACR18. @NEJM #CheckMate227 https://t.co/R84INPrbE2
This phase III study shows superior progression-free survival with first-line combination immunotherapy in a predefined population of NSCLC patients with high tumor mutation burden @ASCOPost https://t.co/xBERr2Y3bR #CheckMate227 #lungcancer
Last Seen Hashtags on Sotwe
下着ぶっかけ
Seen from Japan
MGAI
Dekisugi
Seen from Vietnam
beylikduzugay
Seen from Turkey
supjav
Seen from Indonesia
FireSafeButterflyValve
Seen from United States
killthatlittlebluepiggybitch
Seen from United States
heleners
Seen from Italy
footmassage
Seen from Turkey
President_Trump_2024
Seen from Indonesia
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers